{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:33:02Z","timestamp":1793392382121,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","award":["honorarium\/expenses"],"award-info":[{"award-number":["honorarium\/expenses"]}],"id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","award":["AI083005"],"award-info":[{"award-number":["AI083005"]}],"id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","award":["AI075165"],"award-info":[{"award-number":["AI075165"]}],"id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oy H. Lundbeck"},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen Pharmaceutica"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Carlos and Marguerite Mason Trust","id":[{"id":"https:\/\/ror.org\/01mp16582","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.biopsych.2011.04.013","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T12:57:08Z","timestamp":1308488228000},"page":"663-671","source":"Crossref","is-referenced-by-count":1600,"title":["Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects"],"prefix":"10.1016","volume":"70","author":[{"given":"Brian J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Seabolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2011.04.013_bib1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2008.04.005","article-title":"General and specific cognitive deficits in schizophrenia: Goliath defeats David?","volume":"64","author":"Dickinson","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archpsyc.1967.01730190003001","article-title":"Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques","volume":"16","author":"Heath","year":"1967","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/archpsyc.1967.01730190012002","article-title":"Schizophrenia as an immunologic disorder. II. Effects of serum protein fractions on brain function","volume":"16","author":"Heath","year":"1967","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archpsyc.1967.01730190026003","article-title":"Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function","volume":"16","author":"Heath","year":"1967","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/sj.npp.1300217","article-title":"Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype","volume":"28","author":"Garver","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0165-1781(99)00053-0","article-title":"Elevated interleukin-6 in schizophrenia","volume":"87","author":"van Kammen","year":"1999","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2006.02.003","article-title":"An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives","volume":"84","author":"Nunes","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"M\u00fcller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"M\u00fcller","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.biopsych.2011.04.013_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1054\/mehy.2000.1203","article-title":"The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms","volume":"56","author":"Schwarz","year":"2001","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.biopsych.2011.04.013_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: Microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","article-title":"To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers","volume":"23","author":"O'Connor","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2011.04.013_bib18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0920-9964(00)00156-0","article-title":"Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia","volume":"50","author":"Kowalski","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02190280","article-title":"Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients","volume":"246","author":"Wilke","year":"1996","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s004060050051","article-title":"Autoantibodies against 60-kDa heat shock protein in schizophrenia","volume":"248","author":"Schwarz","year":"1998","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881108089583","article-title":"Kynurenine pathway in psychosis: Evidence of increased tryptophan degradation","volume":"23","author":"Barry","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(98)00140-6","article-title":"Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration","volume":"37","author":"Akiyama","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0920-9964(95)00089-5","article-title":"Serum cytokine concentrations in patients with schizophrenia","volume":"20","author":"Baker","year":"1996","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/JBCPP.1995.6.1.61","article-title":"Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients","volume":"6","author":"Barak","year":"1995","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpsychires.2009.08.008","article-title":"Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood-CSF barrier dysfunction","volume":"44","author":"Bechter","year":"2010","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1192\/bjp.157.1.136","article-title":"Serum interferon in first psychotic attack","volume":"157","author":"Becker","year":"1990","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709000315","article-title":"Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia","volume":"12","author":"Bresee","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0278-5846(01)00221-4","article-title":"Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study","volume":"26","author":"Cazzullo","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000148197","article-title":"Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia","volume":"15","author":"Coelho","year":"2008","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.biopsych.2011.04.013_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.psychres.2006.08.005","article-title":"Interleukin-12 plasma levels in drug-na\u00efve patients with a first episode of psychosis: Effects of antipsychotic drugs","volume":"158","author":"Crespo-Facorro","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.schres.2008.03.018","article-title":"Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: Association with the metabolic syndrome in patients?","volume":"102","author":"Drexhage","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/147323000203000313","article-title":"Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia","volume":"30","author":"Ebrin\u00e7","year":"2002","journal-title":"J Int Med Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0278-5846(93)90072-Z","article-title":"Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects","volume":"17","author":"el-Mallakh","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09629350123895","article-title":"Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment","volume":"10","author":"Erba\u011fci","year":"2001","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.biopsych.2011.04.013_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02900219","article-title":"Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission","volume":"247","author":"Frommberger","year":"1997","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/archpsyc.1989.01810030098018","article-title":"Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects","volume":"46","author":"Ganguli","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(94)90042-6","article-title":"Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness","volume":"51","author":"Ganguli","year":"1994","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jpsychires.2009.10.011","article-title":"Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia","volume":"44","author":"Garc\u00eda-Miss Mdel","year":"2010","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0920-9964(92)90006-Q","article-title":"Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected","volume":"6","author":"Gattaz","year":"1992","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","article-title":"Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis","volume":"33","author":"Haack","year":"1999","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1399-5618.2009.00757.x","article-title":"Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor","volume":"11","author":"Hope","year":"2009","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2011.04.013_bib44","first-page":"439","article-title":"Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients","volume":"49","author":"Kaminska","year":"2001","journal-title":"Arch Immunol. Ther Exp (Warsz)"},{"key":"10.1016\/j.biopsych.2011.04.013_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000119130","article-title":"Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients","volume":"30","author":"Katila","year":"1994","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00207450108986549","article-title":"Effect of risperidone on serum cytokines","volume":"111","author":"Kim","year":"2001","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/sj.mp.4001084","article-title":"The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs","volume":"7","author":"Kim","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib49","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.pnpbp.2004.05.047","article-title":"Th1, Th2 and Th3 cytokine alteration in schizophrenia","volume":"28","author":"Kim","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000213565","article-title":"Cytokine changes and tryptophan metabolites in medication-na\u00efve and medication-free schizophrenic patients","volume":"59","author":"Kim","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib51","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1176\/ajp.150.9.1408","article-title":"Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients","volume":"150","author":"Licinio","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib53","first-page":"206","article-title":"Interleukin level in CSF of patients with first episode schizophrenia","volume":"17","author":"Lu","year":"2003","journal-title":"Chinese Mental Health Journal"},{"key":"10.1016\/j.biopsych.2011.04.013_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2011.04.013_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF02190412","article-title":"Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression","volume":"244","author":"Maes","year":"1995","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0022-3956(94)00049-W","article-title":"Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers","volume":"29","author":"Maes","year":"1995","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0920-9964(96)00029-1","article-title":"Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs","volume":"21","author":"Maes","year":"1996","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-977X(99)00062-0","article-title":"Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics","volume":"10","author":"Maes","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(97)00036-X","article-title":"Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment","volume":"71","author":"Monteleone","year":"1997","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib62","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0924-9338(97)84789-X","article-title":"Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients","volume":"12","author":"M\u00fcller","year":"1997","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib63","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02922260","article-title":"Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia","volume":"247","author":"M\u00fcller","year":"1997","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0920-9964(96)00014-X","article-title":"Elevated circulating levels of IL-6 in schizophrenia","volume":"20","author":"Naudin","year":"1996","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0920-9964(97)00059-5","article-title":"A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?","volume":"26","author":"Naudin","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib66","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/ajp.156.11.1725","article-title":"Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes","volume":"156","author":"Nikkil\u00e4","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000067805","article-title":"Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: No evidence of intrathecal inflammation","volume":"46","author":"Nikkil\u00e4","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib68","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ajmg.1320600517","article-title":"Association study of schizophrenia and the IL-2 receptor beta chain gene","volume":"60","author":"Nimgaonkar","year":"1995","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.biopsych.2011.04.013_bib69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.psychres.2007.11.014","article-title":"Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia","volume":"160","author":"O'Brien","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib70","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.intimp.2005.10.004","article-title":"Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines","volume":"6","author":"Pae","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib71","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/ajp.142.10.1184","article-title":"Serum interferon in patients with psychosis","volume":"142","author":"Preble","year":"1985","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archpsyc.1989.01810030097017","article-title":"Elevated levels of soluble interleukin 2 receptors in schizophrenia","volume":"46","author":"Rapaport","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02191517","article-title":"Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins","volume":"243","author":"Rapaport","year":"1993","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib74","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0006-3223(94)91137-1","article-title":"Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients","volume":"35","author":"Rapaport","year":"1994","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0447.1994.tb01599.x","article-title":"Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia","volume":"90","author":"Rapaport","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2011.04.013_bib76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0278-5846(97)00082-1","article-title":"An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients","volume":"21","author":"Rapaport","year":"1997","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(97)00008-X","article-title":"CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers","volume":"25","author":"Rapaport","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib78","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1176\/ajp.152.9.1291","article-title":"Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status","volume":"152","author":"McAllister","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib79","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0269881107077609","article-title":"Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment","volume":"21","author":"Sarandol","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib80","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1006\/jaut.1996.0086","article-title":"No evidence for autoimmunity in schizophrenia","volume":"9","author":"Schattner","year":"1996","journal-title":"J Autoimmun"},{"key":"10.1016\/j.biopsych.2011.04.013_bib81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s004060050051","article-title":"Autoantibodies against 60-kDa heat shock protein in schizophrenia","volume":"248","author":"Schwarz","year":"1998","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib82","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0024-3205(91)90112-O","article-title":"Serum interleukin-6 in schizophrenic patients","volume":"49","author":"Shintani","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2011.04.013_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2009.05.005","article-title":"Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients","volume":"47","author":"Singh","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.biopsych.2011.04.013_bib84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","article-title":"Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients","volume":"134","author":"Sirota","year":"2005","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib85","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/mp.2009.52","article-title":"Activation of brain interleukin-1beta in schizophrenia","volume":"14","author":"S\u00f6derlund","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0920-9964(00)00007-4","article-title":"Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients","volume":"47","author":"Theodoropoulou","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exnr.1996.0200","article-title":"TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid","volume":"142","author":"Vawter","year":"1996","journal-title":"Exp Neurol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0893-133X(96)00143-1","article-title":"Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients","volume":"16","author":"Vawter","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib90","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.schres.2008.09.001","article-title":"Altered interleukin-3 serum levels in drug-na\u00efve and neuroleptic-treated schizophrenic patients","volume":"106","author":"Xiu","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0033291700027410","article-title":"An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia","volume":"24","author":"Yang","year":"1994","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2011.04.013_bib92","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.plefa.2003.08.015","article-title":"Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia","volume":"69","author":"Yao","year":"2003","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.biopsych.2011.04.013_bib93","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0920-9964(01)00296-1","article-title":"Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology","volume":"57","author":"Zhang","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1192\/bjp.164.2.251","article-title":"Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia","volume":"164","author":"Xu","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib95","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib96","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.npp.1300756","article-title":"Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics","volume":"30","author":"Zhang","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2011.04.013_bib97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-008-1295-4","article-title":"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics","volume":"201","author":"Zhang","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2011.04.013_bib98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-008-1447-6","article-title":"Superoxide dismutase and cytokines in chronic patients with schizophrenia: Association with psychopathology and response to antipsychotics","volume":"204","author":"Zhang","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2011.04.013_bib99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/1468-2389.00156","article-title":"Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge","volume":"8","author":"Hunter","year":"2000","journal-title":"Int J Sel Assess"},{"key":"10.1016\/j.biopsych.2011.04.013_bib100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF00920636","article-title":"Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases","volume":"13","author":"al-Janadi","year":"1993","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humimm.2009.09.351","article-title":"Serum cytokine elevations in celiac disease: Association with disease presentation","volume":"71","author":"Manavalan","year":"2010","journal-title":"Hum Immunol"},{"key":"10.1016\/j.biopsych.2011.04.013_bib102","first-page":"35","article-title":"Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia","volume":"18","author":"Ganguli","year":"1997"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2011.04.013_bib103","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1055\/s-2004-832668","article-title":"Mechanisms of relapse prevention in schizophrenia","volume":"37","author":"M\u00fcller","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2011.04.013_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S026418010000059X","article-title":"The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics","volume":"15","author":"Shepherd","year":"1989","journal-title":"Psychol Med.Monogr Suppl"},{"key":"10.1016\/j.biopsych.2011.04.013_bib105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(91)90073-Z","article-title":"Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia","volume":"5","author":"Wyatt","year":"1991","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2011.04.013_bib106","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1160\/TH08-07-0421","article-title":"Compensatory anti-inflammatory response syndrome","volume":"101","author":"Adib-Conquy","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.biopsych.2011.04.013_bib107","first-page":"1","article-title":"An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces","volume":"24","author":"Drexhage","year":"2011","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322311004045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322311004045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T10:02:46Z","timestamp":1686132166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322311004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0006322311004045"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2011.04.013","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}